Clinical Trial of Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) Oxygen in Women Having Planned Caesarean Delivery (THRIVEN90)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, NW1 2BU
- UCLH
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- scheduled to undergo elective caesarean delivery
- singleton pregnancy
- American Society of Anaesthesiologists (ASA) Physical Status Grade II
- gestational age between 37 - 42 weeks
Exclusion Criteria:
- multiple pregnancy
- pre-eclampsia
- known fetal abnormality
- maternal cardio-respiratory comorbidity
- Body Mass Index (BMI) > 35 kg/m2.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of vital capacity breaths required using THRIVE to pre-oxygenate 90% of parturients to an end tidal oxygen concentration of ≥90% (EN90). End tidal oxygen concentration >= 0.9
Time Frame: 8 months study period
|
measure end tidal oxygen concentration through breathing system attached to anaesthetic machine
|
8 months study period
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
EN90 using THRIVE with mouth open versus mouth closed
Time Frame: 8 months study period
|
to measure any difference in end tidal oxygen concentration after using THRIVE mouth closed versus THRIVE mouth open
|
8 months study period
|
|
comfort score of THRIVE
Time Frame: 8 months study period
|
using 4-point Likert scale (1 being very uncomfortable- 4 comfortable)
|
8 months study period
|
|
changes in fetal wellbeing during pre-oxygenation time
Time Frame: 8 months study period
|
using fetal cardiotocography
|
8 months study period
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 18/0042
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.